

Mark Verrill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6547267/publications.pdf>

Version: 2024-02-01

28
papers

1,420
citations

623574

14
h-index

580701

25
g-index

28
all docs

28
docs citations

28
times ranked

2379
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials. <i>BMC Cancer</i> , 2010, 10, 337.	1.1	560
2	Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. <i>Lancet</i> , The, 2009, 373, 1681-1692.	6.3	168
3	Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma. <i>Journal of Clinical Oncology</i> , 2002, 20, 3533-3544.	0.8	141
4	Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). <i>Annals of Oncology</i> , 2019, 30, 766-773.	0.6	78
5	Conventional Adjuvant Chemotherapy Versus Single-Cycle, Autograft-Supported, High-Dose, Late-Intensification Chemotherapy in High-Risk Breast Cancer Patients: A Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1076-1083.	3.0	64
6	An investigation into the psychometric properties of the Hospital Anxiety and Depression Scale in patients with breast cancer. <i>Health and Quality of Life Outcomes</i> , 2005, 3, 41.	1.0	63
7	Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2017, 18, 929-945.	5.1	58
8	Hormonal therapy for postmenopausal breast cancer: the science of sequencing. <i>Breast Cancer Research and Treatment</i> , 2007, 103, 149-160.	1.1	41
9	Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 667-674.	1.1	32
10	Tourette's Syndrome in New Zealand. <i>British Journal of Psychiatry</i> , 1994, 164, 263-266.	1.7	30
11	Unrecognised severe vitamin D deficiency. <i>BMJ: British Medical Journal</i> , 2008, 336, 1371-1374.	2.4	29
12	The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1485-1495.	1.1	28
13	Capecitabine and vinorelbine in metastatic breast cancer. <i>European Journal of Cancer</i> , 2009, 45, 2253-2265.	1.3	26
14	Desmoplastic Small Round-Cell Tumor of the Pancreas. <i>Journal of Clinical Oncology</i> , 2007, 25, 1440-1442.	0.8	15
15	A Phase I and Pharmacokinetic Study of Ixabepilone in Combination with Carboplatin in Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2008, 14, 8288-8294.	3.2	14
16	Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study. <i>Oncologist</i> , 2018, 23, 1137-1143.	1.9	12
17	A Guideline for the Management of Gastrointestinal Stromal Tumour (GIST). <i>Sarcoma</i> , 2002, 6, 83-87.	0.7	10
18	Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancer. <i>European Journal of Cancer</i> , 2016, 55, 27-37.	1.3	10

#	ARTICLE	IF	CITATIONS
19	Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study. <i>Breast</i> , 2021, 60, 199-205.	0.9	9
20	BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer. <i>Cancers</i> , 2022, 14, 2596.	1.7	8
21	The rise of oncology biosimilars: from process to promise. <i>Future Oncology</i> , 2019, 15, 3255-3265.	1.1	7
22	A Phase I/II Study of a 72-h Continuous Infusion of Etoposide in Advanced Soft Tissue Sarcoma. <i>Sarcoma</i> , 1997, 1, 149-154.	0.7	6
23	Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland. <i>Clinical Sarcoma Research</i> , 2020, 10, 9.	2.3	5
24	HER2 testing in patients with breast cancer. <i>BMJ</i> , The, 2012, 344, e3958-e3958.	3.0	4
25	Randomized multicenter trial of 3 weekly cabazitaxel versus weekly paclitaxel chemotherapy in the first-line treatment of HER2 negative metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 1008-1008.	0.8	2
26	Introduction to sessions on 'Optimizing the implementation of future treatments – time to abandon traditional methods'. <i>Breast Cancer Research</i> , 2008, 10, S21.	2.2	0
27	High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First results of a randomized trial. <i>Women's Oncology Review</i> , 2005, 5, 41-43.	0.0	0
28	High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First results of a randomized trial. <i>Women's Oncology Review</i> , 2005, 5, 41-43.	0.0	0